Skip to content
The Kids Research Institute Australia logo

Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants

In February 2025, Australia introduced maternal vaccination with bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) in the National Immunization Program for pregnant individuals from 28 weeks' gestation as the primary, year-round strategy to prevent RSV disease in infants 6 months of age or younger.

Citation:
Wadia U, Ong MM, Cox SN, Le H, Foo D, Wolf Mankiewicz S, ……. Moore HC, Hayford K, ……. Richmond PC. Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants. JAMA Pediatr. 2026;10.1001/jamapediatrics.2026.3391.

Keywords:
Vaccination; immunization; respiratory syncytial virus; RSV; pregnancy; infants

Abstract:
In February 2025, Australia introduced maternal vaccination with bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) in the National Immunization Program for pregnant individuals from 28 weeks' gestation as the primary, year-round strategy to prevent RSV disease in infants 6 months of age or younger.